Forskning ved Københavns Universitet - Københavns Universitet

Forside

Double-blind trial of bestatin in HIV-positive patients

Publikation: Bidrag til tidsskriftTidsskriftartikel

Standard

Double-blind trial of bestatin in HIV-positive patients. / Hørding, M; Gøtzsche, P C; Dalh Christensen, L; Bygbjerg, Ib Christian; Faber, V.

I: Biomedicine & Pharmacotherapy, Bind 44, Nr. 9, 01.01.1990, s. 475-8.

Publikation: Bidrag til tidsskriftTidsskriftartikel

Harvard

Hørding, M, Gøtzsche, PC, Dalh Christensen, L, Bygbjerg, IC & Faber, V 1990, 'Double-blind trial of bestatin in HIV-positive patients', Biomedicine & Pharmacotherapy, bind 44, nr. 9, s. 475-8.

APA

Hørding, M., Gøtzsche, P. C., Dalh Christensen, L., Bygbjerg, I. C., & Faber, V. (1990). Double-blind trial of bestatin in HIV-positive patients. Biomedicine & Pharmacotherapy, 44(9), 475-8.

Vancouver

Hørding M, Gøtzsche PC, Dalh Christensen L, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. Biomedicine & Pharmacotherapy. 1990 jan 1;44(9):475-8.

Author

Hørding, M ; Gøtzsche, P C ; Dalh Christensen, L ; Bygbjerg, Ib Christian ; Faber, V. / Double-blind trial of bestatin in HIV-positive patients. I: Biomedicine & Pharmacotherapy. 1990 ; Bind 44, Nr. 9. s. 475-8.

Bibtex

@article{5ee481e66f2447219a14e88baaecd0c3,
title = "Double-blind trial of bestatin in HIV-positive patients",
abstract = "Twenty-two HIV-positive homosexual men with a moderately impaired immune system were randomized to bestatin capsules 60 mg a day or placebo for 4 weeks. None suffered from opportunistic infections. The immunomodulating effect of bestatin was investigated by lymphocyte proliferation assay with pokeweed mitogen, phytohaemagglutinin, and concanavalin A, surface marker analysis of T-helper/T-suppressor cells by flow cytometry, natural killer cell activity, beta-2-microglobulin and HIV antibody quantitation. No significant differences between bestatin and placebo in immunological, haematological, biochemical or clinical variables were detected.",
keywords = "Adjuvants, Immunologic, Aminopeptidases, Double-Blind Method, HIV Infections, HIV Seropositivity, Humans, Leucine, Male",
author = "M H{\o}rding and G{\o}tzsche, {P C} and {Dalh Christensen}, L and Bygbjerg, {Ib Christian} and V Faber",
year = "1990",
month = "1",
day = "1",
language = "English",
volume = "44",
pages = "475--8",
journal = "Biomedicine & Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "9",

}

RIS

TY - JOUR

T1 - Double-blind trial of bestatin in HIV-positive patients

AU - Hørding, M

AU - Gøtzsche, P C

AU - Dalh Christensen, L

AU - Bygbjerg, Ib Christian

AU - Faber, V

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Twenty-two HIV-positive homosexual men with a moderately impaired immune system were randomized to bestatin capsules 60 mg a day or placebo for 4 weeks. None suffered from opportunistic infections. The immunomodulating effect of bestatin was investigated by lymphocyte proliferation assay with pokeweed mitogen, phytohaemagglutinin, and concanavalin A, surface marker analysis of T-helper/T-suppressor cells by flow cytometry, natural killer cell activity, beta-2-microglobulin and HIV antibody quantitation. No significant differences between bestatin and placebo in immunological, haematological, biochemical or clinical variables were detected.

AB - Twenty-two HIV-positive homosexual men with a moderately impaired immune system were randomized to bestatin capsules 60 mg a day or placebo for 4 weeks. None suffered from opportunistic infections. The immunomodulating effect of bestatin was investigated by lymphocyte proliferation assay with pokeweed mitogen, phytohaemagglutinin, and concanavalin A, surface marker analysis of T-helper/T-suppressor cells by flow cytometry, natural killer cell activity, beta-2-microglobulin and HIV antibody quantitation. No significant differences between bestatin and placebo in immunological, haematological, biochemical or clinical variables were detected.

KW - Adjuvants, Immunologic

KW - Aminopeptidases

KW - Double-Blind Method

KW - HIV Infections

KW - HIV Seropositivity

KW - Humans

KW - Leucine

KW - Male

M3 - Journal article

C2 - 2081275

VL - 44

SP - 475

EP - 478

JO - Biomedicine & Pharmacotherapy

JF - Biomedicine & Pharmacotherapy

SN - 0753-3322

IS - 9

ER -

ID: 33891108